Share

RECIST news and updates

Hear Lesley Seymour and Jan Bogaerts  discuss with Helen Saul of EJC News the challenges and possibilities for RECIST

The RECIST Working Group was established in 1995 to review the objective response criteria in use at the time and to explore the utility of the use of unidimensional measurements in response assessment, as proposed by NCIC CTG. The initial working group was led by academic members of the EORTC, NCIC CTG and NCI (USA), with a database being created and maintained under the governance of the EORTC. Over the years, the membership of the Working Group was expanded to include other interested or expert members, including some representation from the pharmaceutical industry, as original members joined pharma, or expertise was identified. RECIST v1 was successfully implemented in 2000, and an update (RECIST 1.1) was released in 2009.

At the TAT Congress held in Paris on 2-4 March 2015, Lesley Seymour (NCIC Clinical Trials Group, Canada and co-chair of the RECIST Working Group) and Jan Bogaerts (Methodology Director EORTC Headquarters in Brussels) respectively chaired and spoke at a ‘Beyond RECIST’ session.

Visit the RECIST Working Group website.

Back to news list

Related News

  • PRESS RELEASE: Better treatment for better health: lifting the veil on treatment optimisation

  • Long-term follow-up of chemoradiotherapy treatment in glioma patients shows significantly increased survival

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older patients with acute myeloid leukemia

  • Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

  • EORTC and Alliance Healthcare’s continued partnership in support of SPECTA clinical research infrastructure

  • Results of radiotherapy quality assurance in the PEACE-1 trial show high adherence to protocol

  • EORTC presents new precision medicine research results at AACR 2022

  • Joining forces to optimise cancer treatments in clinical practice: EMA & EORTC launch Cancer Medicines Forum with academia

  • MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

  • Promising results for the ultra-low risk patient group in latest MINDACT analysis